Quote · The Peter Attia Drive
#396 ‒ Breast cancer screening: understanding risk, deciding when to start and how often to screen, and choosing the right imaging strategy
Where this was said
How often should you screen?
At 33:06 · chapter starts 30:15
The debate between annual and biennial mammography is one of the most consequential and most misunderstood in preventive medicine. Peter Attia starts by acknowledging an important evidentiary gap: no randomised controlled trial has ever directly compared the two intervals with mortality as its primary endpoint. Every recommendation rests on modelling studies and observational data. The most important models come from CISNet, commissioned three times by the USPSTF. Counterintuitively, the same CISNet data that the USPSTF used to justify biennial screening have been interpreted by other major cancer and radiology groups as supporting annual screening. The resolution lies in understanding which question is being asked. The USPSTF asked: what gives the best population-level trade-off between benefit, cost, and false positives? The answer to that question may indeed be biennial. But if the question is what gives an individual woman the best chance of not dying from breast cancer, CISNet's 2024 comprehensive analysis — which incorporated both 2D digital mammography and DBT — answers clearly: annual screening of women aged 40–79 produced a 42% mortality reduction versus 30% for biennial, corresponding to 230 versus 165 life-years gained per 1,000 women [1] — Peter Attia "Annual vs biennial: 42% vs 30% mortality reduction: CISNet's 2024 analysis found annual screening reduces breast cancer mortality by 42% ve…" 32:15 . Importantly, while annual screening produces more cumulative false positives, the per-exam false positive rate is actually lower for annual screeners, likely because radiologists have a more recent baseline image for comparison. Observational data reinforce the models: annual screeners had an interval cancer rate of 11% versus 38% for biennial screeners, and 76% versus 56% stage 1 diagnosis rates [2] — Peter Attia "Interval cancers: 11% annual vs 38% biennial: Among women with breast cancer aged 40–84, annual screeners had far fewer interval cancers (1…" 33:30 . Attia's verdict is unambiguous: 'If your goal is to maximize your chances of avoiding death from breast cancer as an individual, annual mammography is the better strategy.'
CISNet's own 2024 models show annual screening reduces breast cancer mortality by 42% versus 30% for biennial — 230 life-years gained per 1,000 women versus 165. The biennial recommendation was built for population budgets, not individual survival.
CISNet's 2024 analysis found annual screening reduces breast cancer mortality by 42% versus 30% for biennial — translating to 230 vs 165 life-years gained per 1,000 women.
Among real women with breast cancer, annual screeners had an 11% interval cancer rate versus 38% for biennial screeners, and a 76% versus 56% rate of stage 1 diagnosis. These are not marginal differences — they are survival-relevant.
Among women with breast cancer aged 40–84, annual screeners had far fewer interval cancers (11%) versus biennial screeners (38%), and were more likely to have stage 1 diagnoses.
